Steven W Pipe

List of Publications by Year
in descending order

188	6,754	66234	71532
papers	citations	42 h-index	76 g-index

192	192	192	4871
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hemophilia A gene therapy: current and next-generation approaches. Expert Opinion on Biological Therapy, 2022, 22, 1099-1115.	1.4	22
2	Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. New England Journal of Medicine, 2022, 386, 1013-1025.	13.9	157
3	Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study. European Journal of Haematology, 2022, 108, 518-527.	1.1	7
4	Defibrotide Therapy for SARS-CoV-2 ARDS. Chest, 2022, 162, 346-355.	0.4	7
5	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	7
6	Gene therapy: Practical aspects of implementation. Haemophilia, 2022, 28, 44-52.	1.0	11
7	Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies â€“ a spotlight on hemophilia. Expert Opinion on Biological Therapy, 2022, 22, 1091-1098.	1.4	1
8	Delivering on the promise of gene therapy for haemophilia. Haemophilia, 2021, 27, 114-121.	1.0	21
9	Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Reviews, 2021, 47, 100759.	2.8	40
10	Management of COVIDâ€19â€associated coagulopathy in persons with haemophilia. Haemophilia, 2021, 27, 41-48.	1.0	14
11	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. Haemophilia, 2021, 27, 19-25.	1.0	6
12	Mortality in congenital hemophilia AÂâ€“Âa systematic literature review. Journal of Thrombosis and Haemostasis, 2021, 19, 6-20.	1.9	41
13	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood, 2021, 137, 2231-2242.	0.6	133
14	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis, 2021, 19, 32-41.	1.9	14
15	The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet, The, 2021, 397, 630-640.	6.3	71
16	Diagnosis and management of von Willebrand disease: A communityâ€wide effort to deliver evidenceâ€based clinical practice guidelines. Haemophilia, 2021, 27, 181-183.	1.0	1
17	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	1.0	9
18	Evolution of haemophilia integrated care in the era of gene therapy: Treatment centreâ€™s readiness in United States and EU. Haemophilia, 2021, 27, 511-514.	1.0	13

#	Article	IF	Citations
19	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	1.0	21
20	Phage display broadly identifies inhibitorâ€reactive regions in von Willebrand factor. Journal of Thrombosis and Haemostasis, 2021, 19, 2702-2709.	1.9	4
21	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis, 2021, 19, 21-31.	1.9	7
22	Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, e772-e775.	1.0	8
23	Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data. Journal of Comparative Effectiveness Research, 2021, 10, 1323-1336.	0.6	5
24	First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years. Blood, 2021, 138, 3971-3971.	0.6	5
25	Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. Blood, 2021, 138, 3195-3195.	0.6	1
26	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial. Blood, 2021, 138, 3972-3972.	0.6	0
27	Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'. Blood, 2021, 138, 592-592.	0.6	2
28	Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome. Blood, 2021, 138, 3237-3237.	0.6	0
29	Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). Blood, 2021, 138, LBA-3-LBA-3.	0.6	12
30	Acquired von Willebrand Syndrome in an Infant With Coarctation of the Aorta and Williams Syndrome. World Journal for Pediatric & Congenital Heart Surgery, 2020, 11, NP91-NP93.	0.3	1
31	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
32	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	1.9	24
33	The role of telemedicine in the delivery of health care in the COVIDâ€19 pandemic. Haemophilia, 2020, 26, e230-e231.	1.0	57
34	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Thrombosis and Haemostasis, 2020, 120, 728-736.	1.8	19
35	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	1.0	14
36	Antiâ€factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors. Journal of Thrombosis and Haemostasis, 2020, 18, 1653-1660.	1.9	4

#	Article	IF	Citations
37	Biological mechanisms underlying interâ€individual variation in factor VIII clearance in haemophilia. Haemophilia, 2020, 26, 575-583.	1.0	29
38	Not in the genotype: can unexplained hemophilia A result from â€œmicro(RNA) managementâ€?. Transfusion, 2020, 60, 227-228.	0.8	4
39	First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A - BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII. Blood, 2020, 136, 44-45.	0.6	10
40	Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study. Blood, 2020, 136, 3-4.	0.6	3
41	Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results. Blood, 2020, 136, 36-37.	0.6	3
42	In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Î‘ Plasma with and without Inhibitors. Blood, 2020, 136, 41-42.	0.6	0
43	Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices. Blood, 2020, 136, 14-15.	0.6	0
44	Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 610-615.	1.0	8
45	The evolution of recombinant factor replacement for hemophilia. Transfusion and Apheresis Science, 2019, 58, 596-600.	0.5	15
46	Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 575-580.	1.0	6
47	Gene editing in hemophilia: a â€œCRISPRâ€•choice?. Blood, 2019, 133, 2733-2734.	0.6	6
48	Comparison of Activated Protein C Resistance With Factor V Leiden Testing by Molecular Assay. American Journal of Clinical Pathology, 2019, 152, S5-S5.	0.4	0
49	New treatment paradigm for hemophilia poses challenges for legacy bioassays. Journal of Thrombosis and Haemostasis, 2019, 17, 1446-1448.	1.9	0
50	How we approach: Training pediatric coagulationists. Pediatric Blood and Cancer, 2019, 66, e27982.	0.8	1
51	Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. Molecular Therapy - Methods and Clinical Development, 2019, 15, 170-178.	1.8	55
52	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematology,the, 2019, 6, e295-e305.	2.2	252
53	Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intraâ€atrial thrombosis in severe haemophilia with an inhibitor. Haemophilia, 2019, 25, e203-e205.	1.0	9
54	Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Advances, 2019, 3, 2748-2750.	2.5	26

#	Article	IF	Citations
55	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances, 2019, 3, 3241-3247.	2.5	85
56	New therapies for hemophilia. Blood, 2019, 133, 389-398.	0.6	120
57	Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events. Blood, 2019, 134, 1138-1138.	0.6	11
58	One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B. Blood, 2019, 134, 3348-3348.	0.6	4
59	Congenital Bleeding Disorders. , 2019, , 95-110.		0
60	First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A. Blood, 2019, 134, 4630-4630.	0.6	7
61	HIF1-alpha Regulates Acinar Cell Function and Response to Injury in Mouse Pancreas. Gastroenterology, 2018, 154, 1630-1634.e3.	0.6	14
62	Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A withÂinhibitorsâ€"A retrospective analysis. Haemophilia, 2018, 24, 245-252.	1.0	39
63	Gene therapy for hemophilia. Pediatric Blood and Cancer, 2018, 65, e26865.	0.8	30
64	Emicizumab for hemophilia A with factor VIII inhibitors. Expert Review of Hematology, 2018, 11, 835-846.	1.0	22
65	Novel therapeutics for hemophilia and other bleeding disorders. Blood, 2018, 132, 23-30.	0.6	46
66	Bioengineered molecules for the management of haemophilia: Promise and remaining challenges. Haemophilia, 2018, 24, 68-75.	1.0	10
67	Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies. Blood, 2018, 132, 1187-1187.	0.6	5
68	The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics. Blood, 2018, 132, 1190-1190.	0.6	0
69	Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure. Blood, 2018, 132, 2500-2500.	0.6	1
70	Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. American Journal of Hematology, 2017, 92, 940-945.	2.0	5
71	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	1.0	18
72	A Cornucopia of Therapies under Study for Hemophilia. Molecular Therapy, 2017, 25, 2429-2430.	3.7	4

#	Article	IF	Citations
73	The Role of Platelets and Îµ-Aminocaproic Acid in Arthrogryposis, Renal Dysfunction, and Cholestasis (ARC) Syndrome Associated Hemorrhage. Pediatric Blood and Cancer, 2016, 63, 561-563.	0.8	14
74	Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood, 2016, 128, 2007-2016.	0.6	165
75	What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?. Hematology American Society of Hematology Education Program, 2016, 2016, 648-649.	0.9	9
76	New therapies for hemophilia. Hematology American Society of Hematology Education Program, 2016, 2016, 650-656.	0.9	33
77	Coagulation status after therapeutic plasma exchange using citrate in kidney transplant recipients. Transfusion, 2016, 56, 3073-3080.	0.8	10
78	Recognizing the need for personalization of haemophilia patientâ€reported outcomes in the prophylaxis era. Haemophilia, 2016, 22, 825-832.	1.0	36
79	Argatroban monitoring: aPTT versus chromogenic assay. American Journal of Hematology, 2016, 91, E303-4.	2.0	9
80	Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. Haemophilia, 2016, 22, 514-520.	1.0	58
81	Perinatal hematology. Seminars in Fetal and Neonatal Medicine, 2016, 21, 1.	1.1	7
82	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	0.6	3
83	Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine. Blood, 2015, 126, 1237-1244.	0.6	37
84	Improving Hematologist/Oncologist Knowledge and Confidence in Managing Hemophilia through Online Educational Interventions. Blood, 2015, 126, 5593-5593.	0.6	0
85	Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHwI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries. Blood, 2015, 126, 2302-2302.	0.6	5
86	Factor VIII therapy for hemophilia A: current and future issues. Expert Review of Hematology, 2014, 7, 373-385.	1.0	27
87	Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia, 2014, 20, 200-206.	1.0	15
88	A von Willebrand factor fragment containing the Dâ€²D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood, 2014, 124, 445-452.	0.6	60
89	Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis. Blood, 2014, 124, 689-689.	0.6	4
90	Innovations in coagulation: improved options for treatment of hemophilia A and B. Thrombosis Research, 2013, 131, S1.	0.8	14

#	Article	IF	Citations
91	Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thrombosis and Haemostasis, 2013, 110, 931-939.	1.8	35
92	Thrombin-Stimulated Platelets Have Functional Binding Sites For Factor VIIIa That Are Distinct From Phosphatidylserine. Blood, 2013, 122, 3582-3582.	0.6	0
93	Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity. Blood, 2012, 120, 1923-1932.	0.6	32
94	Characterization of central venous catheterâ€“associated deep venous thrombosis in infants. Journal of Pediatric Surgery, 2012, 47, 1159-1166.	0.8	49
95	Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop. Journal of Thrombosis and Haemostasis, 2012, 10, 107-115.	1.9	22
96	Onâ€demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia, 2012, 18, 255-262.	1.0	16
97	Outcomes of mentored, grantâ€funded fellowship training in haemostasis /thrombosis: findings from a nested caseâ€“control survey study. Haemophilia, 2012, 18, 326-331.	1.0	3
98	Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia, 2012, 18, 332-338.	1.0	29
99	The hope and reality of longâ€acting hemophilia products. American Journal of Hematology, 2012, 87, S33-9.	2.0	45
100	Factors for life: advances in the treatment of congenital and coagulopathic bleeding disorders. Thrombosis Research, 2011, 128, S1.	0.8	0
101	A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function. Blood, 2011, 117, 3181-3189.	0.6	46
102	Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping. Journal of Thrombosis and Haemostasis, 2011, 9, 1183-1190.	1.9	26
103	Functional factorÂVIII made with von Willebrand factor at high levels in transgenic milk. Journal of Thrombosis and Haemostasis, 2011, 9, 2235-2242.	1.9	14
104	Elucidation of the Roles of Individual Asparagine-Linked Glycans Outside of the B Domain on Factor VIII Secretion. Blood, 2011, 118, 2238-2238.	0.6	3
105	Conservative Mutations in the Membrane-Binding Motif of Factor V C2 Domain to Residues of Pseudonaja Textilis Venom Factor V Confer Phosphatidylserine-Independent Activity. Blood, 2011, 118, 2243-2243.	0.6	0
106	In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood, 2010, 116, 6114-6122.	0.6	54
107	Hemophilia: New Protein Therapeutics. Hematology American Society of Hematology Education Program, 2010, 2010, 203-209.	0.9	42
108	Prophylactic therapy with Fibrogammin^{Â®} P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia, 2010, 16, 316-321.	1.0	52

#	Article	IF	Citations
109	Go long! A touchdown for factor VIII?. Blood, 2010, 116, 153-154.	0.6	10
110	Suppression of FVIII Inhibitor Formation in Hemophilic Mice by Delivery of Transgene Modified Apoptotic Fibroblasts. Molecular Therapy, 2010, 18, 214-222.	3.7	17
111	Understanding Ectopically Expressed Factor VIII (F8) In Megakaryocytes: Implications for Optimum Platelet-Delivered F8 Activity for Gene Therapy. Blood, 2010, 116, 2205-2205.	0.6	4
112	Asparagine-Linked Glycosylation at the NH2-Terminus Does Not Influence Secretion or Function of Coagulation Factors V and VIII. Blood, 2010, 116, 2220-2220.	0.6	0
113	Endoplasmic Reticulum to Mitochondria Ca2+ Signaling Inhibits Factor VIII Secretion and Mediates Oxidative Stress and Apoptosis Upon Factor VIII Expression. Blood, 2010, 116, 2212-2212.	0.6	0
114	Experience with a third generation recombinant factor VIII concentrate (Advate^{Â®}) for immune tolerance induction in patients with haemophilia A. Haemophilia, 2009, 15, 718-726.	1.0	20
115	Reduction of inhibitor titres by infusion of FVIII gene transduced tolerogenic dendritic cells in haemophilic mice. Haemophilia, 2009, 15, 634-634.	1.0	0
116	Functional roles of the factor VIII B domain. Haemophilia, 2009, 15, 1187-1196.	1.0	86
117	Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factorÂXa-correlated activated partial thromboplastin time. Journal of Thrombosis and Haemostasis, 2009, 7, 80-86.	1.9	58
118	Visions in haemophilia care. Thrombosis Research, 2009, 124, S2-S5.	0.8	11
119	Management of Neonatal Aortic Arch Thrombosis With Low-molecular Weight Heparin. Journal of Pediatric Hematology/Oncology, 2009, 31, 516-521.	0.3	19
120	Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics: Targets and Therapy, 2009, 3, 117.	3.0	15
121	Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.. Blood, 2009, 114, 4443-4443.	0.6	0
122	Strategies to Enhance the Efficacy of Platelet-Derived Factor (F) VIII: Studies with Inactivation Resistant FVIII (IR8) and Canine FVIII in Hemophilia A Mice.. Blood, 2009, 114, 3496-3496.	0.6	0
123	Membrane-Interactive Amino Acids in the Factor VIII C1 Domain Are Cooperative with C2 Domain Epitopes for Membrane Binding and Cofactor Function.. Blood, 2009, 114, 848-848.	0.6	0
124	The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Data From the Pediatric Registry.. Blood, 2009, 114, 2990-2990.	0.6	0
125	Risk for Post Thrombotic Syndrome (PTS) Development in Children with Extremity Deep Venous Thrombosis (DVT): Results of the US Centers for Disease Control and Prevention (CDC) Pediatric Thrombosis and Hemostasis Centers.. Blood, 2009, 114, 4000-4000.	0.6	1
126	Lactadherin blocks thrombosis and hemostasis inÂvivo: correlation with platelet phosphatidylserine exposure. Journal of Thrombosis and Haemostasis, 2008, 6, 1167-1174.	1.9	82

#	Article	IF	Citations
127	Establishment of embryonic stem cells secreting human factorÂVIII for cellâ€based treatment of hemophiliaÂA. Journal of Thrombosis and Haemostasis, 2008, 6, 1352-1359.	1.9	26
128	Recombinant clotting factors. Thrombosis and Haemostasis, 2008, 99, 840-850.	1.8	96
129	Bleeding Disorders. Pediatrics in Review, 2008, 29, 121-130.	0.2	22
130	Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18525-18530.	3.3	593
131	Post-thrombotic Syndrome in Children: A Single Center Experience. Journal of Pediatric Hematology/Oncology, 2008, 30, 261-266.	0.3	44
132	Incremental Improvement in Bioengineering of Coagulation Factor VIII for Efficient Expression: Elimination of a Dispensable Disulfide Loop Enhances Secretion. Blood, 2008, 112, 3073-3073.	0.6	5
133	Reduction of Inhibitory Anti-FVIII Antibody Titer by Using a B Domain Variant FVIII/N6 cDNA for Nonviral Gene Therapy in Hemophilia a Mice. Blood, 2008, 112, 3537-3537.	0.6	4
134	Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time. Blood, 2008, 112, 435-435.	0.6	10
135	Most Factor VIII B Domain Missense Mutations Are Unlikely to Be Causative Mutations for Hemophilia A: Implications for Factor VIII Genetic Analysis. Blood, 2008, 112, 513-513.	0.6	0
136	Use of rFVIIa in Individuals with Congenital Hemophilia B Complicated by Alloantibody Inhibitors to Factor IX: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004â€“2008). Blood, 2008, 112, 4521-4521.	0.6	0
137	Bleeding Disorders. Pediatrics in Review, 2008, 29, 121-130.	0.2	6
138	The Enhancing Effects of the Light Chain on Heavy Chain Secretion in Split Delivery of Factor VIII Gene. Molecular Therapy, 2007, 15, 1856-1862.	3.7	39
139	Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors. Molecular Therapy, 2007, 15, 2080-2087.	3.7	45
140	Treatment of Thrombosis With Fondaparinux (Arixtra) in a Patient With End-stage Renal Disease Receiving Hemodialysis Therapy. Journal of Pediatric Hematology/Oncology, 2007, 29, 581-584.	0.3	23
141	Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. Journal of Thrombosis and Haemostasis, 2007, 5, 901-906.	1.9	54
142	The U.S. Thrombosis and Hemostasis Centers pilot sites program. Journal of Thrombosis and Thrombolysis, 2007, 23, 1-7.	1.0	20
143	The Mutations SER2117â†'LEU, and TRP/TRP2063/64â†'MET/PHE in the Hydrophobic Spikes of the Factor V C2 Domain Lead to Tenacious Phospholipid Binding and Suggest a Mechanism through Which Phosphatidylserine Activates the Prothrombinase Complex.. Blood, 2007, 110, 2703-2703.	0.6	0
144	An Expanded Post-Thrombosis Sequelae Assessment Scale in Children.. Blood, 2007, 110, 3196-3196.	0.6	0

#	Article	IF	Citations
145	Consideration in Hemophilia Therapy Selection. Seminars in Hematology, 2006, 43, S23-S27.	1.8	14
146	Management of Hemophilia in the Midst of Emerging Pathogens: A Societal Perspective. Seminars in Hematology, 2006, 43, S1-S3.	1.8	1
147	Neonatal thromboembolic emergencies. Seminars in Fetal and Neonatal Medicine, 2006, 11, 198-206.	1.1	67
148	The physician's role in selecting a factor replacement therapy. Haemophilia, 2006, 12, 21-25.	1.0	5
149	339. FIV Lentiviral Vector Gene Transfer for Hemophilia A. Molecular Therapy, 2006, 13, S129.	3.7	0
150	Induction of Tolerance to FVIII in Hemophilic Mice by Delivery of Apoptotic Syngeneic Fibroblasts Expressing a FVIII Transgene.. Blood, 2006, 108, 768-768.	0.6	0
151	An Essential Role of the Factor VIII Light Chain in Facilitating Heavy Chain Secretion.. Blood, 2006, 108, 4034-4034.	0.6	0
152	Hemostasis and Thrombosis Centers Pilot Sites Registry: Thrombophilia Evaluation in Children.. Blood, 2006, 108, 3298-3298.	0.6	0
153	Prevention of Early Arteriovenous Fistula Failure Due to Thromosis: Experience with Primary Thromboprophylaxis.. Blood, 2006, 108, 885-885.	0.6	0
154	Prophylactic Therapy with Fibrogammin Is Associated with a Decreased Incidence of Bleeding Episodes: A Retrospective Case Control Study.. Blood, 2006, 108, 1014-1014.	0.6	1
155	Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.. Blood, 2006, 108, 1604-1604.	0.6	0
156	Antioxidants Improve Factor VIII Secretion in the Liver by Preventing Oxidative Stress, Activation of the Unfolded Protein Response, and Apoptosis.. Blood, 2006, 108, 197-197.	0.6	0
157	Combined factor V and factor VIII deficiency in a Thai patient: a case report of genotype and phenotype characteristics. Haemophilia, 2005, 11, 280-284.	1.0	20
158	The promise and challenges of bioengineered recombinant clotting factors. Journal of Thrombosis and Haemostasis, 2005, 3, 1692-1701.	1.9	85
159	Regulated Phosphatidylserine Exposure on Platelets Mediates Fibrin Formation in Hemostasis and Thrombosis.. Blood, 2005, 106, 1645-1645.	0.6	1
160	The Secretion Efficiency of Factor VIII Can Be Regulated by the Size and Oligosaccharide Content of the B Domain.. Blood, 2005, 106, 687-687.	0.6	5
161	Reduction of Anti-FVIII Inhibitor Titers in Hemophilic Mice Infused with Syngeneic Apoptotic Cells Expressing a Human FVIII Transgene.. Blood, 2005, 106, 216-216.	0.6	49
162	Coagulation Factors with Improved Properties for Hemophilia Gene Therapy. Seminars in Thrombosis and Hemostasis, 2004, 30, 227-237.	1.5	23

#	Article	IF	Citations
163	New high-technology products for the treatment of haemophilia. Haemophilia, 2004, 10, 55-63.	1.0	28
164	Bioengineering of coagulation factor VIII for improved secretion. Blood, 2004, 103, 3412-3419.	0.6	193
165	His2315/Gln2316 of the Factor VIII C2 Domain Interact with Phospholipid Membranes and Influence Activity of the Factor Xase Complex.. Blood, 2004, 104, 1727-1727.	0.6	0
166	The future of recombinant coagulation factors. Journal of Thrombosis and Haemostasis, 2003, 1, 922-930.	1.9	47
167	LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII1. Journal of Thrombosis and Haemostasis, 2003, 1, 2360-2367.	1.9	57
168	Tricuspid Valve Thrombus and Pulmonary Embolus in an Infant with Homozygous Thermolabile Methylenetetrahydrofolate Reductase and Heterozygous Prothrombin G20210A Variant. Journal of Perinatology, 2003, 23, 513-515.	0.9	2
169	Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nature Genetics, 2003, 34, 220-225.	9.4	282
170	Biosynthetic origin and functional significance of murine platelet factor V. Blood, 2003, 102, 2851-2855.	0.6	32
171	Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-binding and von Willebrand Factor-binding Motifs. Journal of Biological Chemistry, 2002, 277, 6374-6381.	1.6	103
172	Neonatal Sinovenous Thrombosis Associated With Homozygous Thermolabile Methylenetetrahydrofolate Reductase in Both Mother and Infant. Journal of Perinatology, 2002, 22, 175-178.	0.9	12
173	Expression of Factor VIII in Recombinant and Transgenic Systems. Blood Cells, Molecules, and Diseases, 2002, 28, 234-248.	0.6	32
174	Hemophilia A Mutations within the Factor VIII A2-A3 Subunit Interface Destabilize Factor VIIIa and Cause One-stage/ Two-stage Activity Discrepancy. Thrombosis and Haemostasis, 2002, 88, 781-787.	1.8	43
175	Molecular defects in coagulation Factor VIII and their impact on Factor VIII function. Vox Sanguinis, 2002, 83, 89-96.	0.7	10
176	Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thrombosis and Haemostasis, 2002, 88, 781-7.	1.8	11
177	Inferior vena cavectomy for nonexcisable Wilms' tumor thrombus. Journal of Pediatric Surgery, 2001, 36, 526-529.	0.8	14
178	Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood, 2001, 97, 685-691.	0.6	93
179	A chamber of hope for hemophilia. Nature Biotechnology, 2000, 18, 264-265.	9.4	3
180	Regulation of Factor VIII Expression and Activity by von Willebrand Factor. Thrombosis and Haemostasis, 1999, 82, 201-208.	1.8	52

#	Article	IF	Citations
181	Mannose-dependent Endoplasmic Reticulum (ER)-Golgi Intermediate Compartment-53-mediated ER to Golgi Trafficking of Coagulation Factors V and VIII. Journal of Biological Chemistry, 1999, 274, 32539-32542.	1.6	117
182	Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones Calnexin and Calreticulin. Journal of Biological Chemistry, 1998, 273, 8537-8544.	1.6	137
183	Mutagenesis of a Potential Immunoglobulin-binding Protein-binding Site Enhances Secretion of Coagulation Factor VIII. Journal of Biological Chemistry, 1997, 272, 24121-24124.	1.6	94
184	Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11851-11856.	3.3	122
185	Neonatal purpura fulminans in association with factor V R506Q mutation. Journal of Pediatrics, 1996, 128, 706-709.	0.9	55
186	Factor VIII C2 Domain Missense Mutations Exhibit Defective Trafficking of Biologically Functional Proteins. Journal of Biological Chemistry, 1996, 271, 25671-25676.	1.6	47
187	Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. Journal of Pediatric Surgery, 1993, 28, 1137-1139.	0.8	89
188	Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics: Targets and Therapy, 0, , 117.	3.0	1